- Home
- RAPT
as 04-18-2025 1:42pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 117.5M | IPO Year: | 2019 |
| Target Price: | $5.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $8.58 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
GlobeNewswire
a month ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
a month ago
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Clinical Trials Arena
2 months ago
Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer
Zacks
2 months ago
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy
GlobeNewswire
3 months ago
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
3 months ago
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
TipRanks
4 months ago
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.